BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29971626)

  • 1. Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women.
    Bedi JS; Mayo RM; Truong K; Chen L; Dickes L; Sherrill WW; Jones K
    Breast Cancer Res Treat; 2018 Oct; 171(3):759-765. PubMed ID: 29971626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors.
    Bedi JS; Mayo RM; Chen L; Dickes L; Sherrill WW; Jones K
    J Oncol Pharm Pract; 2020 Jan; 26(1):36-42. PubMed ID: 30885081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
    Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
    Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
    Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
    Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
    Farias AJ; Du XL
    Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors.
    Spencer JC; Reeve BB; Troester MA; Wheeler SB
    Psychooncology; 2020 Apr; 29(4):647-654. PubMed ID: 32048400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.
    Heiney SP; Truman S; Babatunde OA; Felder TM; Eberth JM; Crouch E; Wickersham KE; Adams SA
    Am J Clin Oncol; 2020 Jul; 43(7):504-509. PubMed ID: 32251120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
    Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.
    Bowles EJA; Ramin C; Buist DSM; Feigelson HS; Weinmann S; Veiga LHS; Bodelon C; Curtis RE; Vo JB; Berrington de Gonzalez A; Gierach GL
    Breast Cancer Res Treat; 2022 May; 193(1):203-216. PubMed ID: 35275285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
    Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
    J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
    Jacob L; Hadji P; Kostev K
    J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
    Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
    J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa.
    Ayeni OA; Chiwambutsa S; Chen WC; Kapungu N; Kanji C; Thelingwani R; Murugan N; Mathiba R; Phakathi B; Nietz S; Ramiah D; O'Neil DS; Jacobson JS; Ruff P; Cubasch H; Chirwa T; Joffe M; Masimirembwa C; Neugut AI
    Breast Cancer Res Treat; 2023 Feb; 197(3):647-659. PubMed ID: 36538247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
    Rosenberg SM; Zheng Y; Gelber S; Ruddy KJ; Poorvu P; Sella T; Tamimi RM; Wassermann J; Schapira L; Borges VF; Come S; Peppercorn J; Sepucha KR; Partridge AH
    Breast Cancer Res Treat; 2023 Feb; 197(3):547-558. PubMed ID: 36436128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
    Partridge AH; Wang PS; Winer EP; Avorn J
    J Clin Oncol; 2003 Feb; 21(4):602-6. PubMed ID: 12586795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer.
    Reeder-Hayes KE; Mayer SE; Lund JL
    Cancer; 2021 Apr; 127(8):1220-1227. PubMed ID: 33508140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.
    Reeder-Hayes KE; Meyer AM; Dusetzina SB; Liu H; Wheeler SB
    Breast Cancer Res Treat; 2014 Jun; 145(3):743-51. PubMed ID: 24789443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution.
    Hwang GS; Paranjpe R; Opsomer C; Lu K; Abajue U; Abughosh S; Zaghloul H; Trivedi MV
    Clin Breast Cancer; 2020 Dec; 20(6):520-526. PubMed ID: 32669209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.